Testimony from the bedside: from Coley's toxins to targeted immunotherapy.
A new clinical study reported in the New England Journal of Medicine unveils the long-awaited outcome of anti-CTLA-4 therapy for melanoma. It provides grounds for continued enthusiasm for cancer immunotherapy, deepens our thoughts on underlying mechanisms, and suggests exciting next steps.
Park
Jin Mo
JM
Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Cutaneous Biology Research Center, Boston, MA 02114, USA.
Fisher
David E
DE